Olympus EX-President and helpers arrested – falsifying financial statements is a crime

… The Japanese authorities arrested seven central figures in the huge accounting scandal at Olympus — including the camera maker’s former chairman and executive vice president — on Thursday as part of investigations into a decade-long cover-up that has prompted concern over what critics say is lax corporate governance at Japanese companies.

Tsuyoshi Kikukawa, a former chairman and president of Olympus, was arrested in Tokyo along with two other former executives on suspicion of having falsified financial statements, Tokyo prosecutors said. Two former investment bankers suspected of helping to set up the cover-up, and two of their associates, were also arrested.

Olympus said that it was aware of the gravity of the situation and was cooperating fully with the authorities.

A panel of experts hired by Olympus to investigate the cover-up has accused the former executives of masking investment losses racked up in Japan’s bubble economy over a period of at least 13 years. Those losses were eventually accounted for in transactions disguised as merger fees paid to overseas investment funds.

The irregular accounting came to light in October when Olympus fired Michael C. Woodford, who was its president and chief executive. At the time, Mr. Kikukawa attributed the dismissal to Mr. Woodford’s aggressive Western management style. But Mr. Woodford, a Briton, said he had been fired for questioning a series of payouts made by the company between 2006 and 2008, and he provided what he said was evidence to the news media. Mr. Kikukawa subsequently resigned from the company.

Mr. Woodford then began a bid to return to Olympus, whose share price has collapsed since the scandal broke, to lead a turnaround. But he abandoned that bid in December after the company’s biggest domestic shareholders sided against him in a move that some foreign investors have said confirms their worst fears of corporate Japan’s resistance to outsiders and to change.

Mr. Woodford said Thursday in an e-mail that he felt vindicated. “After going to hell and back, this is a day to remember,” he said.

Arrested Thursday on suspicion of violating Japanese securities laws were Mr. Kikukawa; Hisashi Mori, the former executive vice president; and Hideo Yamada, a former auditor, according to a statement issued by the Tokyo prosecutor’s office.

The Japanese authorities also arrested two former Nomura bankers, Akio Nakagawa and Nobumasa Yokoo, along with two of their associates, the statement said. Olympus is also being investigated in the United States and Britain.

Investors are now focusing on how Olympus will shore up its finances, as well as who will lead the company as it battles to regain credibility. In December, it restated five years’ worth of earnings, exposing a $1.1 billion hole in its balance sheet, leading to speculation that it would need to merge with or sell itself to a competitor to stay afloat.

On Monday, Olympus forecast a $410 million loss for its financial year, which ends in March. Still, the current president, Shuichi Takayama, said the company’s mainstay medical equipment business remained robust and that the company might not need to raise outside capital.

Also clouding Olympus’s outlook is the possibility of a delisting from the Tokyo Stock Exchange, which could devastate its share price. The exchange decided last month to keep Olympus listed for the time being, saying a cover-up orchestrated by a few executives did not merit a delisting. But the exchange indicated Thursday that it could revisit that decision based on fresh evidence.

Mr. Takayama has indicated that he will step down at a shareholders’ meeting scheduled for April. He has been sued by Olympus over the scandal, along with 18 other former and current executives, though he is slated to stay on as president until the April handover.

The payouts first questioned by Mr. Woodford involved $687 million in fees Olympus paid to an obscure financial adviser over Olympus’s acquisition of Gyrus, a British medical equipment maker, in 2008. That fee amounted to roughly a third of the $2 billion acquisition price, a fee amount more than 30 times the norm.

He also questioned why Olympus acquired three small companies in Japan for a total of $773 million, only to write down most of their value within the same fiscal year. Those companies — Altis, a medical waste recycling company; Humalabo, a facial cream maker; and News Chef, which makes plastic containers — were unprofitable and had little in common with Olympus’s main lines of business.

The investigative panel hired by Olympus has said these payments in fact masked transactions used by the company to account for the losses it had transferred from its books. (…read more: http://nyti.ms/wEHDM3)


$2 billion acquisition, Akio Nakagawa, Altis, Altis and Humalabo, AXAM, AXAM Investments Inc., Axes, Axes America LLC, Axes America’s President and CEO, Axes Investment Management Co., Axes Securities, Axes Securities Co, bankrupt, British medical company Gyrus, business in financial transactions, Cayman Islands, CEO of ITX, corporate finance, dispute, dormant, Drexel, Drexel Burnham Lambert, Dynamic Dragons, FINRA records, G.C. Venture Capital, Global Chef, Global Company, Global Company’s CEO Yokoo Nobumasa had also been CEO of Humalabo’s predecessor company L.E.M. Hanbai, Gyrus deal, Hajime “Jim” Sagawa, Hajime Sagawa, Hamada Masayuki, Hayashi Masayuki, hide losses, Hirata Kiichi, Humalabo, Ichimura Takuya, independent investigation from the company’s top institutional shareholders, informal capacity, investigations from government, Investment firm, J Alternative, J Bridge/Asia Alliance Holdings, Japanese camera maker Olympus, Kawada Hitoshi, Kobe University in Economics, Kosaka Kiyoshi, Ltd., M&A deal, maker of microwavable plastic, Masayuki Hamada, massive decline in Olympus stock price, Matsumoto Kuniaki, Merrill Lynch, Michael Woodford, Mori Hisashi, Murata Masami, mysterious payment, Nakagawa Akio, Neo Strategic Venture LP, New Investments Ltd., News Chef, Nishihata Youhei, Nishimori Hitoshi, Nissho Iwai, Nobel Prize winning economist, Nomura, Nomura Securities, obscure, Olympus Executive Vice President, Paine Webber, PaineWebber, PricewaterhouseCoopers (PwC), Robert Mundell, Sagawa & Company, Sagawa Capital, Sagawa International Services, Sanyo Securities America, Sato Hideki, shareholders, Sojitz, special-purpose investment vehicles, Takahashi Yoshinori, Tanabe Souhei/Shouhei, Techno Mining Ltd., top executive, two mysterious sets of corporate deals, UBS AG, Wasserstein Perella & Co., www.axesim.co.jp, Yokoo Akinobu, Yokoo Nobumasa, Yoshida Minoru, Yoshikai Ryuzo, Outside The USA (OUS) Global Markets Amid Soft US Sales, To Improve Execution, Optimize Innovation And Accelerate Globalization, accelerating globalization, disruptive business models, each of the major emerging markets, global P&L responsibility, representatives on their staff from each region, global growth goals, strong and collaborative partnership between our business, Haio Fauser is a local market expert in each of the geographic regions, expanding insights into these markets, review our businesses, develop specific plans to accelerate our global growth, multinational, challenging environment, cyclical problem of depressed macroeconomic conditions, constrained healthcare budgets, increased pressure in utilization, the current trajectory of rising healthcare costs is unsustainable, current global economic situation, emerging markets, growth opportunity for our industry, acroMIS Implementation And Development, sustainable growth, slower growth of US markets, delivering better economic value, engaging primarily with the physician, evaluated the merits of our products solely on the clinical value, clinical value, critical decision factor, demonstrate the economic value at both the provider and payer levels, deliver value to the overall healthcare system, economic downturn, we must prioritize our investment, biggest long-term opportunity, meeting the needs of the billions of people in emerging markets, solutions that deliver better economic value, accelerated investments to serve the emerging markets, the future of global economic recovery, cost-effective solutions, around the globe, Evolving Market, medical devices companies, widespread economic uncertainty, reimbursement pressure, declining procedure volume, forced to look for other solutions, restructuring initiatives, focus on emerging markets, nascent technologies, innovation and state-of-the-art medical technology, progressive, age-related disease, the standard of care, many patients with age working against them, myriad of complications, unsuitable for this open surgery, meet the urgent need of patients, delivered through two approaches, first mover advantage, in the OUS market,  enrollment in the pilot study, scheduled for completion, European market, market in Europe, competitive landscape is likely to change, recent launches, devices approved for procedures, Candidates in queue, acquisition of technologies, pivotal trial, targeting a limited launch, CE Mark trial of the next-generation, under development, proper selection of patients, choosing the right delivery method, dealing with high risk complications, overt risk, address the high risk, unfavorable reimbursement decision from the CMS, adverse impact on technology, considered as a first line therapy, Team work, noninvasive, necessity of the procedures to be performed in specialized centers, training of the physicians and staff is significant, Widespread rollout, physicians’ learning curve, physicians may have to perform 30 cases before they attain the desired level of proficiency, proper selection of patients, economic potential of this specialized, state-of-the-art procedure, devices are priced at a hefty premium, prevailing economic uncertainty, adoption of austerity measures, force the players to increasingly compete on price, advantageous position, onditions, high surgical risk, less invasive treatment, acroMIS, Europe, outside the US OUS, providing expertise. early clinical evidence, principle investigator, key opinion leader KOL, first-in-man, implementation, commercialize medtech, Access to capital, burdensome and uncertain regulatory environment, lack of innovation and productivity, threats to the biomedical industry’s growth, biomedical company CEOs, CHI-California Healthcare Institute, BayBio, PwC, The CEO Survey, delay a research or development project, Lack of funding, project delays cited by private company CEOs, the current FDA regulatory approval process has slowed the growth, Findings of the CEO Survey, issues being discussed throughout the biomedical industry by executives, 2012 California Biomedical Industry Report, snapshot of the biomedical industry in California, biomedical cluster, products in clinical development, biomedical innovation, California’s biomedical industry, global leadership position, availability of capital to fund future innovation, regulatory framework that is based on consistency, innovative technologies, Biomedical Access to Capital, seeking diverse funding sources, government grants, angel investors, venture capital, licensing agreements, partnerships, Forty-four percent of biomedical CEOs surveyed said they will look to licensing agreements, corporate partnerships as a source of financing, Corporate venture funding, the investment of corporate funds into external endeavors, source of funding to the industry, corporate venture capital as a finance source, disease foundations/non-governmental organizations, access to capital, tax incentives for innovation, Regulatory Environment will Determine R&D Productivity, coverage and reimbursement issues are extremely important, FDA has the best regulatory approval process in the world, recreate the ecosystem that has made the US the leading biomedical region, Working collaboratively with other stakeholders, Congress, maintain the high standards of safety and effectiveness, address patients’ need, improving our ability to attract investment and grow, pharmaceuticals, biotechnology, medical devices, diagnostics or medical equipment, Implementation, In-country Opportunity Assessment, Innovation, Intellectual Property, IntelliSense Fine Force Technology, international business development experience, International Medical Consulting, Intraluminal, Investment Management, Investor Presentation, Investor Relations, job creation, Joint Ventures, Key Opinion Leader Connections, KOL Physicians, laparoscopic vascular and endovascular capabilities, laparoscopic vascular and endovascular treatments, later stage corporations, leadership position, lower extremity arterial disease, Marketing, MEDICA, Medical, Medical device, medical device industry, medical device innovation, Medical technology, MedTech, Mergers & Acquisitions, Minimal comparative clinical evidence, modality for abdominal aortic aneurysm repair, new medical devices, NIOBE magnets, Off-Shoring, outside the USA, paradigm-changing, Portfolio Management, preclinical evidence, preclinical studies, Private Equity, Product Development, Proof-of-concept Lab Trials, prospective studies, proximal aortic anastomosis, R&D, regulatory and reimbursement processes, regulatory changes, remote device manipulation system, remotely direct the catheter tip, renal aortic pathologies, resources, Robot-assisted intervention, Robot-assisted laparoscopic aortic procedures, robot-assisted laparoscopic aortic surgery, robotic computer-enhanced telemanipulation systems, robotic surgery, robotic technology, Robotically steerable endovascular catheter systems, robotics, services to VC firms, splenic and renal artery aneurysm reconstruction, start-up, steerable catheter, Sterotaxis, Strategic Alliances, Strategic Planning, Strategy Development, surgical robotics, Tactical Execution of Commercialization Programs, Raising money for a startup, serial entrepreneur, Outside The USA (OUS), Global Markets, Improve Execution, Optimize Innovation, Accelerate Globalization, Disruptive business model, Major emerging markets, Global growth goals, Collaborative partnership, Expanding insights into markets, Develop specific plans to accelerate global growth, Multinational, Increased pressure in utilization, Growth opportunity, acroMIS Implementation And Development, Sustainable growth, Slower growth of US markets, Delivering better economic value, Engaging primarily with the physician, Evaluated the merits of products, Clinical value, Demonstrate the economic value, Provider and payer levels, Deliver value, Prioritize investment, Biggest long-term opportunity, Meeting the needs, Solutions that deliver better economic value, Accelerated investments, Cost-effective solutions, Around the globe, Evolving Market, Reimbursement pressure, Declining procedure volume, Look for other solutions, Restructuring initiatives, Focus on emerging markets, Nascent technologies, Innovation and state-of-the-art medical technology, Progressive, Age-related disease, Standard of care, Unsuitable for open surgery, Meet the urgent need of patients, First mover advantage, OUS market,  Enrollment in pilot study, Scheduled for completion, European market, Japanese market, Competitive landscape, Recent launches, Devices approved for procedures, Candidates in queue, Acquisition of technologies, Pivotal trial, Targeting a limited launch, CE Mark trial, Next-generation, Under development, Proper selection of patients, Choosing the right delivery method, Dealing with high risk complications, Overt risk, Address the high risk, Unfavorable reimbursement decision from the CMS, Adverse impact on technology, Considered as a first line therapy, Team work, Noninvasive, Necessity of the procedures to be performed in specialized centers, Training of the physicians and staff, Widespread rollout, Physicians’ learning curve, Attain the desired level of proficiency, Proper selection of patients, Economic potential, State-of-the-art procedure, Devices priced at hefty premium, Prevailing economic uncertainty, Adoption of austerity measures, Compete on price, Advantageous position, Less invasive treatment, Europe, Asia, Germany, Japan, Providing expertise. Early clinical evidence, Principle investigator, Key opinion leader KOL, First-in-man, Implementation, Commercialize medtech, Access to capital, Uncertain regulatory environment, Threats to the biomedical industry’s growth, biomedical company CEOs, CEO, FDA regulatory approval process, Biomedical industry, Biomedical cluster, Products in clinical development, Global leadership position, Availability of capital to fund future innovation, Regulatory framework based on consistency, Innovative technologies, Diverse funding sources, Government grants, Angel investors, Venture capital, Licensing agreements, Partnerships, Corporate partnerships as a source of financing, Corporate venture funding, Investment of corporate funds into external endeavors, Disease foundations, Non-governmental organizations NGO, Access to capital, Tax incentives for innovation, Coverage and reimbursement issues, Regulatory approval process in the world, Recreate the ecosystem, Leading biomedical region, Working collaboratively, Stakeholders, Maintain high standards of safety and effectiveness, Address patients’ need, Improving ability to attract investment and grow, Pharmaceuticals, Biotechnology, Medical devices, Diagnostics or medical equipment

Comments are closed.